By Deena Beasley LOS ANGELES (Reuters) - Two powerful and innovative cholesterol drugs likely to be approved this summer both target the same protein and have been shown to sharply lower LDL in high-risk patients. But there is at least one significant difference between the two offerings: the dosages in which they will be sold. Assuming approval from the U.S. Food and Drug Administration, Amgen Inc. will offer its drug, Repatha, as a biweekly 140 mg injection or a monthly injection of 420 mg, while Praluent, from Regeneron Pharmaceuticals Inc and Sanofi, will be offered in biweekly injections of 75 mg or 150 mg. The difference in dosages is likely to lead to very different sales strategies for the two drugs, in what could be a fierce competition for market share.
A fire at a nursing home in central China left at least 38 people dead, officials said Tuesday, with bodies burned beyond recognition and wheelchairs reduced to charred frames. The fire broke out on Monday evening in an apartment building at a privately-owned old people's home in Pingdingshan, the state news agency Xinhua said. "The bodies were so badly burned, we couldn't tell who was who," Xinhua quoted one victim's relative saying of the identification process.